A group of scientists in Italy have developed a vaccine with the potential to protect against fungal pathogens that commonly infect humans, according to a study by Torosantucci and colleagues in the September 5 issue of The Journal of Experimental Medicine. Although these fungi pose little threat to people with healthy immune systems, they can cause fatal infections in those whose immune systems have been weakened by cancer treatments or post-transplant immunosuppressive therapies. No anti-fungal vaccines are currently available.
The new vaccine was made of a sugar-like molecule called beta-glucan that is found on the cell wall of the fungus and that the fungus needs to grow and survive. To induce a robust immune response to the vaccine, the group attached the relatively innocuous beta-glucan to a protein called diptheria toxin that is known to stimulate the immune system and has been used in other human vaccines.
The vaccine protected rodents from fatal fungal infections by triggering the production of anti-beta-glucan antibodies. These antibodies stuck to the invading fungal cell wall and prevented the fungus from growing. The authors now plan to test the vaccine in humans and hope the results are equally promising.
Nickey Henry | EurekAlert!
Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel
The Nagoya Protocol Creates Disadvantages for Many Countries when Applied to Microorganisms
05.12.2016 | Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
05.12.2016 | Earth Sciences
05.12.2016 | Physics and Astronomy
05.12.2016 | Life Sciences